NEW YORK, NY / ACCESSWIRE / November 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Citigroup Inc. (NYSE:C)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/citigroup-inc-loss-submission-form?prid=10818&wire=1
Lead Plaintiff Deadline: December 29, 2020
Class Period: February 25, 2017 - October 12, 2020
According to the filed complaint, throughout the class period, defendants willfully or recklessly made and/or caused the Company to make false and misleading statements regarding Citi's internal controls and risk management capabilities that failed to disclose the serious and longstanding inadequacy of Citi's internal controls, data governance, compliance risk management, and enterprise risk management. As a result, Defendants' statements about Citi's internal controls and risk management were materially false and/or misleading and/or lacked a reasonable basis.
Royal Caribbean Cruises Ltd. (NYSE:RCL)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10818&wire=1
Lead Plaintiff Deadline: December 7, 2020
Class Period: February 4, 2020 - March 17, 2020
Allegations against RCL include that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
Mesoblast Limited (NASDAQ:MESO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10818&wire=1
Lead Plaintiff Deadline: December 7, 2020
Class Period: April 16, 2019 - October 1, 2020
Allegations against MESO include that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong